{"id":79216,"date":"2026-04-06T12:01:09","date_gmt":"2026-04-06T12:01:09","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/"},"modified":"2026-04-06T12:01:09","modified_gmt":"2026-04-06T12:01:09","slug":"tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/","title":{"rendered":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor"},"content":{"rendered":"<div>\n<ul>\n<li style=\"list-style-position:inside; text-align:center;\"><em>First candidate from Tenvie\u2019s product engine to enter clinical development<\/em><\/li>\n<li style=\"list-style-position:inside; text-align:center;\"><em>Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with obesity <\/em><\/li>\n<li style=\"list-style-position:inside; text-align:center;\"><em>Preliminary data expected in the second half of 2026<\/em>\n<\/li>\n<\/ul>\n<p>BRISBANE, Calif., April  06, 2026  (GLOBE NEWSWIRE) &#8212; Tenvie Therapeutics, a biotechnology company developing precision\u2011engineered small molecule therapies to transform the treatment of neurological and peripheral diseases, today announced the first subject dosed in a Phase 1 clinical study evaluating TNV262, a fully CNS-penetrant small molecule inhibitor targeting NLRP3 for the treatment of cardiometabolic diseases, including obesity and cardiovascular disease (CVD), as well as multiple sclerosis (MS). The Phase 1a\/1b study will evaluate the safety and tolerability of single and multiple ascending doses of TNV262 as well as cardiovascular and inflammatory biomarkers in healthy volunteers and persons with obesity.<\/p>\n<p>\u201cWe are delighted to announce dosing of the first subject in our Phase 1 study of TNV262, an important milestone for Tenvie and our mission to transform the treatment of neurological and peripheral diseases with precision-engineered small molecules, made possible by the dedication of our team,\u201d said Tony Estrada, Ph.D., President &amp; CEO of Tenvie Therapeutics. \u201cThis trial represents the first clinical application of our CNS-first design approach\u2014building maximum CNS penetration into the foundation of our chemistry to precisely engage key biological targets and intervene at the source of disease. We look forward to evaluating the potential of TNV262 across a range of inflammation-driven indications, beginning with cardiometabolic diseases.\u201d<\/p>\n<p>\u201cDysregulation of the NLRP3 pathway has been implicated across multiple diseases characterized by chronic inflammation, including cardiometabolic conditions such as obesity and CVD,\u201d said Tanya Z. Fischer, M.D., Ph.D., Chief Medical Officer at Tenvie Therapeutics. \u201cAlthough clinical validation of NLRP3 has emerged in peripheral indications, many existing programs have been limited by insufficient CNS exposure. As a fully CNS-penetrant NLRP3 inhibitor supported by encouraging preclinical data demonstrating robust suppression of inflammatory CV risk biomarkers, TNV262 is uniquely positioned to deliver disease-modifying effects for people living with obesity and CVD.\u201d<\/p>\n<p>The Phase 1 clinical trial is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of single and multiple ascending doses of TNV262 in healthy volunteers and persons with obesity. Primary outcome measures include the safety and tolerability of TNV262, as well as biomarkers of inflammation and cardiometabolic risk. Secondary outcome measures will assess body weight and body composition, along with measures of appetite and eating behavior in persons with obesity. Tenvie expects to report preliminary safety and PK data in the second half of 2026. Pending positive results, Tenvie intends to initiate Phase 2 studies evaluating TNV262 in CVD and obesity, as well as in MS.<\/p>\n<p>\u201cDespite important advances in cardiometabolic care, many existing therapies primarily address downstream risk factors rather than the biological processes that drive disease progression,\u201d said Donna Ryan, M.D., Professor Emerita at Pennington Biomedical Research Center. \u201cChronic, unresolved inflammation is increasingly recognized as a key contributor to obesity and CVD, and approaches that target neuroinflammatory pathways such as NLRP3 have the potential to meaningfully alter disease trajectory. This trial represents an important step toward transforming the future of care for individuals living with cardiometabolic diseases.\u201d<\/p>\n<p><strong>About TNV262<\/strong><\/p>\n<p>TNV262 is an investigational, fully CNS-penetrant small molecule inhibitor of NLRP3, a key regulator of inflammation within the innate immune system. By modulating a key driver of chronic inflammation across multiple conditions, TNV262 has the potential to address a broad range of inflammation- and neuroinflammation-driven diseases. Initial clinical development is focused on cardiometabolic diseases, including obesity and CVD, as well as MS. The fully CNS-penetrant profile of TNV262 also supports its potential in other diseases characterized by neuroinflammation-mediated disease progression. In preclinical studies, TNV262 demonstrated complete CNS penetrance and a favorable safety profile.<\/p>\n<p><strong>About Tenvie Therapeutics<\/strong><\/p>\n<p>Tenvie Therapeutics is developing precision\u2011engineered small molecule therapies to address core drivers of neurological and peripheral diseases: neuroinflammation and cellular dysfunction. Leveraging its proprietary product engine, Tenvie has the unique ability to advance both fully CNS\u2011penetrant and peripherally restricted products across a broad portfolio. Tenvie\u2019s most advanced program, TNV262, a fully CNS-penetrant NLRP3 inhibitor, is in Phase 1 clinical development for cardiometabolic indications, including obesity and cardiovascular disease, as well as multiple sclerosis. In parallel, Tenvie is advancing TNV108, a peripherally restricted SARM1 allosteric inhibitor targeting peripheral neuropathies, through preclinical development. Tenvie\u2019s clinical pipeline is complemented by discovery-stage programs across a range of related indications.<\/p>\n<p><strong>Investor Contact:<\/strong><br \/>Penelope Belnap<br \/>Precision AQ<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M_8WAe1W7dnjnDnzW5XqKr_3xROS3avAY3-JNZRTPDkRdvKX3E5F69FNSfdJiO7-QqitdELhvo-z7qU5oVDTtJBWq-1TwvQq03OA8CusryjtSL-I-_XyiweGNxSn6ddU07IR9X21KFlEgXS4CkchaQ==\" rel=\"nofollow\" target=\"_blank\" title=\"Penelope.belnap@precisionaq.com\">Penelope.belnap@precisionaq.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2Q2NGYxMmEtMmM1NS00ZDYwLWJjMjctNTU3OTRiNjMxZjA3LTEzMDkxMzUtMjAyNi0wNC0wNi1lbg==\/tiny\/Tenvie-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First candidate from Tenvie\u2019s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with obesity Preliminary data expected in the second half of 2026 BRISBANE, Calif., April 06, 2026 (GLOBE NEWSWIRE) &#8212; Tenvie Therapeutics, a biotechnology company developing precision\u2011engineered small [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-79216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"First candidate from Tenvie\u2019s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending do\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T12:01:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/Y2Q2NGYxMmEtMmM1NS00ZDYwLWJjMjctNTU3OTRiNjMxZjA3LTEzMDkxMzUtMjAyNi0wNC0wNi1lbg==\/tiny\/Tenvie-Therapeutics-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor\",\"datePublished\":\"2026-04-06T12:01:09+00:00\",\"dateModified\":\"2026-04-06T12:01:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\"},\"wordCount\":762,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\",\"name\":\"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-04-06T12:01:09+00:00\",\"dateModified\":\"2026-04-06T12:01:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/","og_locale":"en_US","og_type":"article","og_title":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor","og_description":"First candidate from Tenvie\u2019s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending do","og_url":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-04-06T12:01:09+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/Y2Q2NGYxMmEtMmM1NS00ZDYwLWJjMjctNTU3OTRiNjMxZjA3LTEzMDkxMzUtMjAyNi0wNC0wNi1lbg==\/tiny\/Tenvie-Therapeutics-Inc-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor","datePublished":"2026-04-06T12:01:09+00:00","dateModified":"2026-04-06T12:01:09+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/"},"wordCount":762,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/","url":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/","name":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-04-06T12:01:09+00:00","dateModified":"2026-04-06T12:01:09+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=79216"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79216\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=79216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=79216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=79216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}